Effectiveness of temporary dose increase at recapturing response in patients on maintenance infliximab. (13th March 2011)

• Record Type: Journal Article
• Authors: Irving, P; Sastrillo, M; Duncan, J; Anderson, S; Sanderson, J
• Is Part Of: Gut. Volume 60:(2011)Supplement 1
• Page Start: A204
• Page End: A204
• Publication Date: 2011-03-13
• Subjects: inflammatory bowel disease -- infliximab.; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gut.2011.239301.429
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: Biologic drugs are widely used in Crohn's disease, often with good effect. Unfortunately, even with scheduled maintenance therapy, secondary loss of response is common affecting approximately 10–15% of patients/year. There are two main options for recapturing response; dose increase or interval reduction. Published data suggest that these strategies can recapture response in approximately 75% of patients. However, both of these strategies have cost implications. Anecdotal reports suggest that in patients losing response to regular infusions of infliximab (IFX) 5 mg/kg, a temporary increase to 10 mg/kg for two infusions can lead to subsequent recapture of response at 5 mg/kg. This strategy for dealing with loss of response to IFX was agreed with our PCTs and has been followed recently. The authors aimed to identify what proportion of patients were subsequently able to persist with IFX treatment at 5 mg/kg. Methods: The authors performed a retrospective review of all patients with Crohn's disease who had received double doses of IFX for loss of response since January 2009. Demographic data, HBI prior to the first infusion at the higher dose and prior to the first infusion at the lower dose, and ability to continue on IFX at 5 mg/kg were reviewed. Results: To date, 18 patients (8M:10F, median age 32 (range 19–51)) have received double dose IFX for loss of response. Median disease duration was 5 years (range 1–40) and the median time to dose increase from starting IFX was 15 months (range 6–60). All had received standard induction doses of IFX at 5 mg/kg on weeks 0, 2 and 6 and were on scheduled maintenance therapy. The dose interval prior to dose increase was 8 weeks for 16 patients and 6 weeks for 2. 12 patients were on concurrent immunomodulators and 6 were not (4 – intolerance, 2 – patient choice). To date, full outcome data are available for 11 subjects. Dose increase was effective in most patients in the short term with the median HBI falling from 7 prior to the first infusion at 10 mg/kg, to 3.5 prior to the first infusion back at the standard dose (5 mg/kg). However, the majority (8/11) required transfer onto adalimumab. Six patients who swapped to adalimumab did so prior to, or after one reinfusion of standard dose IFX and two patients after two infusions. Of the three patients who were able to recapture response, two have had three infusions at 5 mg/kg and one patient has had seven. Conclusion: There are clear drug cost advantages to temporary dose increase over permanent dose increase or interval reduction. However, this experience suggests that the ability to maintain patients on IFX using this strategy is likely inferior to permanent changes in dose or treatment interval.